ophthalmologytimes10h
Avirmax Biopharma doses first patient in phase I/IIa clinical trial of ABI-110
ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic ...
ophthalmologytimes16h
Next-generation sequencing in ocular oncology brings advances in diagnosis, management
Differentiating hereditary from nonhereditary retinoblastoma is now possible overnight, improving early intervention ...